232 related articles for article (PubMed ID: 31776402)
1. Phosphorylation of the histone demethylase KDM5B and regulation of the phenotype of triple negative breast cancer.
Yeh IJ; Esakov E; Lathia JD; Miyagi M; Reizes O; Montano MM
Sci Rep; 2019 Nov; 9(1):17663. PubMed ID: 31776402
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the histone demethylase, KDM5B, directly induces re-expression of tumor suppressor protein HEXIM1 in cancer cells.
Montano MM; Yeh IJ; Chen Y; Hernandez C; Kiselar JG; de la Fuente M; Lawes AM; Nieman MT; Kiser PD; Jacobberger J; Exner AA; Lawes MC
Breast Cancer Res; 2019 Dec; 21(1):138. PubMed ID: 31805991
[TBL] [Abstract][Full Text] [Related]
3. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
[TBL] [Abstract][Full Text] [Related]
4. The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers.
Klein BJ; Piao L; Xi Y; Rincon-Arano H; Rothbart SB; Peng D; Wen H; Larson C; Zhang X; Zheng X; Cortazar MA; Peña PV; Mangan A; Bentley DL; Strahl BD; Groudine M; Li W; Shi X; Kutateladze TG
Cell Rep; 2014 Jan; 6(2):325-35. PubMed ID: 24412361
[TBL] [Abstract][Full Text] [Related]
5. Histone demethylase lysine demethylase 5B in development and cancer.
Han M; Xu W; Cheng P; Jin H; Wang X
Oncotarget; 2017 Jan; 8(5):8980-8991. PubMed ID: 27974677
[TBL] [Abstract][Full Text] [Related]
6. Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27.
Wang D; Han S; Peng R; Jiao C; Wang X; Yang X; Yang R; Li X
J Exp Clin Cancer Res; 2016 Feb; 35():37. PubMed ID: 26911146
[TBL] [Abstract][Full Text] [Related]
7. KDM5B is a master regulator of the H3K4-methylome in stem cells, development and cancer.
Xhabija B; Kidder BL
Semin Cancer Biol; 2019 Aug; 57():79-85. PubMed ID: 30448242
[TBL] [Abstract][Full Text] [Related]
8. Histone lysine demethylase KDM5B maintains chronic myeloid leukemia via multiple epigenetic actions.
Xue S; Lam YM; He Z; Zheng Y; Li L; Zhang Y; Li C; Mbadhi MN; Zheng L; Cheng Z; Liu Y; Wang X; Chan LC; Ng RK; Zhang J
Exp Hematol; 2020 Feb; 82():53-65. PubMed ID: 32007477
[TBL] [Abstract][Full Text] [Related]
9. KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family.
Enkhbaatar Z; Terashima M; Oktyabri D; Tange S; Ishimura A; Yano S; Suzuki T
Cell Cycle; 2013 Jul; 12(13):2100-12. PubMed ID: 23759590
[TBL] [Abstract][Full Text] [Related]
10. SUMOylation negatively modulates target gene occupancy of the KDM5B, a histone lysine demethylase.
Bueno MT; Richard S
Epigenetics; 2013 Nov; 8(11):1162-75. PubMed ID: 23970103
[TBL] [Abstract][Full Text] [Related]
11. Coordinated regulation of retinoic acid signaling pathway by KDM5B and polycomb repressive complex 2.
Zhang Y; Liang J; Li Q
J Cell Biochem; 2014 Sep; 115(9):1528-38. PubMed ID: 24619877
[TBL] [Abstract][Full Text] [Related]
12. Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A).
Wong PP; Miranda F; Chan KV; Berlato C; Hurst HC; Scibetta AG
Mol Cell Biol; 2012 May; 32(9):1633-44. PubMed ID: 22371483
[TBL] [Abstract][Full Text] [Related]
13. The PHD1 finger of KDM5B recognizes unmodified H3K4 during the demethylation of histone H3K4me2/3 by KDM5B.
Zhang Y; Yang H; Guo X; Rong N; Song Y; Xu Y; Lan W; Zhang X; Liu M; Xu Y; Cao C
Protein Cell; 2014 Nov; 5(11):837-50. PubMed ID: 24952722
[TBL] [Abstract][Full Text] [Related]
14. Overexpressed KDM5B is associated with the progression of glioma and promotes glioma cell growth via downregulating p21.
Dai B; Hu Z; Huang H; Zhu G; Xiao Z; Wan W; Zhang P; Jia W; Zhang L
Biochem Biophys Res Commun; 2014 Nov; 454(1):221-7. PubMed ID: 25450384
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway.
Hayami S; Yoshimatsu M; Veerakumarasivam A; Unoki M; Iwai Y; Tsunoda T; Field HI; Kelly JD; Neal DE; Yamaue H; Ponder BA; Nakamura Y; Hamamoto R
Mol Cancer; 2010 Mar; 9():59. PubMed ID: 20226085
[TBL] [Abstract][Full Text] [Related]
16. KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance.
Xu W; Zhou B; Zhao X; Zhu L; Xu J; Jiang Z; Chen D; Wei Q; Han M; Feng L; Wang S; Wang X; Zhou J; Jin H
Int J Biol Sci; 2018; 14(9):1122-1132. PubMed ID: 29989047
[TBL] [Abstract][Full Text] [Related]
17. H3K4 demethylase KDM5B regulates cancer cell identity and epigenetic plasticity.
He R; Xhabija B; Gopi LK; Kurup JT; Xu Z; Liu Z; Kidder BL
Oncogene; 2022 May; 41(21):2958-2972. PubMed ID: 35440714
[TBL] [Abstract][Full Text] [Related]
18. Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target.
Zheng YC; Chang J; Wang LC; Ren HM; Pang JR; Liu HM
Eur J Med Chem; 2019 Jan; 161():131-140. PubMed ID: 30343192
[TBL] [Abstract][Full Text] [Related]
19. A truncated and catalytically inactive isoform of KDM5B histone demethylase accumulates in breast cancer cells and regulates H3K4 tri-methylation and gene expression.
Di Nisio E; Licursi V; Mannironi C; Buglioni V; Paiardini A; Robusti G; Noberini R; Bonaldi T; Negri R
Cancer Gene Ther; 2023 Jun; 30(6):822-832. PubMed ID: 36697763
[TBL] [Abstract][Full Text] [Related]
20. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor.
Kristensen LH; Nielsen AL; Helgstrand C; Lees M; Cloos P; Kastrup JS; Helin K; Olsen L; Gajhede M
FEBS J; 2012 Jun; 279(11):1905-14. PubMed ID: 22420752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]